Castle Biosciences, Inc.
CSTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -3.6% | -2% | 1.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 77.5% | 79.5% | 81.4% | 81.3% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 6.3% | 3.8% | 4% | 15.9% |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -0.6% | 5.2% | -29.4% | 11.1% |
| EPS Diluted | -0.02 | 0.15 | -0.9 | 0.32 |
| % Growth | -113.3% | 116.7% | -381.3% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |